Physician profile
Alan Vela
NPI 1538664578
$454.78
in general payments reported to CMS, 2019-2025
10 companies · $86.97 in 2025
The $86.97 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $129 · 2024: $239 · 2025: $86.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $150.82 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $89.67 | 2024-2025 | |
| Averitas Pharma INC. | $34.47 | 2023-2025 | Qutenza |
| Jazz Pharmaceuticals INC. | $34.36 | 2025 | |
| Acadia Pharmaceuticals INC | $31.50 | 2024 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $29.55 | 2024 | Hyqvia |
| Abbvie INC. | $28.22 | 2024 | |
| Amneal Pharmaceuticals LLC | $21.84 | 2024 | Rytary |
| Teva Pharmaceuticals USA, INC. | $18.32 | 2024 | Austedo Xr |
| Insightec,INC | $16.03 | 2024 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Vela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.